Holen Sie sich die Stockscreener-App
14.27
5.16%
0.70
Vorhandelsmarkt:
14.02
-0.25
-1.75%
Schlusskurs vom Vortag:
$13.57
Offen:
$13.95
24-Stunden-Volumen:
515.64K
Relative Volume:
0.76
Marktkapitalisierung:
$779.10M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-6.0211
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+19.92%
1M Leistung:
+23.12%
6M Leistung:
+34.62%
1J Leistung:
-2.13%
1-Tages-Spanne:
$13.92
$14.41
1-Wochen-Bereich:
$11.89
$14.78
52-Wochen-Spanne:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
14.27 | 740.88M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize
Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest
What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com
What analysts say about Stoke Therapeutics Inc. stockRapid growth opportunities - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Is Stoke Therapeutics Inc. a good long term investmentExceptional profit velocity - PrintWeekIndia
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Published on: 2025-07-18 11:35:29 - jammulinksnews.com
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser
What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser
Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):